Stocks of CymaBay Therapeutics Inc. (NASDAQ:CBAY) traded higher last session on Wall Street, up 5.21% to $11.52.
According to the data, CymaBay Therapeutics Inc. (NASDAQ:CBAY) has 11 analysts covering its stock. The consensus rating among analysts is ‘Buy’. As we calculate the median target price by taking the range between a high of $19.00 and a low of $8.00, we find $15.00. Given the previous closing price of $10.95, this indicates a potential upside of 36.99 percent. CBAY stock price is now 23.01% away from the 50-day moving average and 69.32% away from the 200-day moving average. The market capitalization of the company currently stands at $1.16B.
A total of 0 analysts have issued a hold rating and 11 have given it a buy rating. Brokers who have rated the stock have averaged $14.50 as their price target over the next twelve months.
In other news, Quinlan Paul T, General Counsel sold 5,000 shares of the company’s stock on Jun 30. The stock was sold for $50,250 at an average price of $10.05. Upon completion of the transaction, the General Counsel now directly owns 0 shares in the company, valued at $0.0. An SEC document containing details of the transaction can be found on the SEC’s website. On Jun 20, President of R&D McWherter Charles sold 21,749 shares of the business’s stock. A total of $177,383 was realized by selling the stock at an average price of $8.16. This leaves the insider owning 15,000 shares of the company worth $0.17 million. Insiders disposed of 146,849 shares of company stock worth roughly $1.69 million over the past 1 year. A total of 0.31% of the company’s stock is owned by insiders.
There have been several recent changes in the stakes of large investors in CBAY stock. A new stake in CymaBay Therapeutics Inc. shares was purchased by BAIN CAPITAL LIFE SCIENCES INVESTORS, LLC during the first quarter worth $29,250,000. CORMORANT ASSET MANAGEMENT, LP invested $14,876,000 in shares of CBAY during the first quarter. In the first quarter, VOLORIDGE INVESTMENT MANAGEMENT, LLC acquired a new stake in CymaBay Therapeutics Inc. valued at approximately $7,533,000. JENNISON ASSOCIATES LLC acquired a new stake in CBAY for approximately $7,297,000. HEALTHCARE OF ONTARIO PENSION PLAN TRUST FUND purchased a new stake in CBAY valued at around $4,523,000 in the second quarter. In total, there are 162 active investors with 76.30% ownership of the company’s stock.
Monday’s opening bell rang with an opening price of $11.05 for CymaBay Therapeutics Inc. (NASDAQ: CBAY). During the past 12 months, CymaBay Therapeutics Inc. has had a low of $2.66 and a high of $11.38. As of last week, the company has a debt-to-equity ratio of 0.91, a current ratio of 5.20, and a quick ratio of 5.20. The fifty day moving average price for CBAY is $9.39 and a two-hundred day moving average price translates $6.84 for the stock.
The latest earnings results from CymaBay Therapeutics Inc. (NASDAQ: CBAY) was released for Mar, 2023. According to the Biotechnology Company, earnings per share came in at -$0.29, missing analysts’ expectations of -$0.09 by -0.2. This compares to -$0.32 EPS in the same period last year. The company reported revenue of $26.88 million for the quarter, compared to $24.5 million a year earlier. Comparatively to last year’s same quarter, the company’s quarterly revenue rose 9.68 percent. For the current quarter, analysts expect CBAY to generate $12.8M in revenue.
CymaBay Therapeutics Inc.(CBAY) Company Profile
CymaBay Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and providing therapies to treat liver and other chronic diseases. Its lead product candidate is seladelpar (MBX-8025), a selective agonist of peroxisome proliferator activated receptor delta for the treatments of autoimmune liver disease, primary biliary cholangitis (PBC). The company also develops MBX-2982 for the disease/condition of hypoglycemia in type 1 diabetics. It has a license agreement with ABW Cyclops SPV LP to support development of seladelpar for the treatment of PBC; and holds a worldwide license from Janssen Pharmaceuticals, Inc. to research, develop, and commercialize compounds with activity against an undisclosed metabolic disease target. The company was formerly known as Metabolex, Inc. CymaBay Therapeutics, Inc. was incorporated in 1988 and is headquartered in Newark, California.
